Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, but there is deficiency of early diagnosis biomarkers and therapeutic targets. Drug-resistance account for most HCC-related deaths, yet the mechanisms underlying drug-resistance remain poorly understood.